Inaba T, Shimazaki C, Sumikuma T, Takahashi R, Hirai H, Kikuta T, Sudo Y, Yamagata N, Ashihara E, Goto H, Fujita N, Yoshimura M, Nakagawa M
Department of Clinical Laboratory and Medicine, Kyoto Prefectural University of Medicine, Japan.
Int J Hematol. 1997 Oct;66(3):315-23. doi: 10.1016/s0925-5710(97)00051-0.
We analyzed the expression of the Thy-1 antigen (CD90) in CD34+ acute leukemia using two-color flow cytometry. Leukemic cells were obtained from the bone marrow (BM) and/or the peripheral blood (PB) of 57 patients: 37 with acute myelogenous leukemia (AML) including nine with secondary AML following myelodysplastic syndrome (MDS/AML), and 20 with acute lymphoblastic leukemia (ALL) including three with chronic myelogenous leukemia in blast crisis (CML-BC) of the lymphoid type. Among these patients, one (3.6%) with de novo AML, two (22.2%) with MDS/AML, three (17.6%) with de novo ALL, and two (66.7%) with CML-BC coexpressed CD34 and Thy-1 (CD34+ Thy-1+) on more than 20% of the mononuclear cells within 'lymph' plus 'blast' window. Thy-1 was rarely expressed in de novo acute leukemia especially in AML. Interestingly, in 1 patient with CML-BC, the leukemic cells in BM were divided into two subpopulations (CD34+ Thy-1low and CD34+ Thy-1high), whereas most of the CD34+ leukemic cells in PB were Thy-1high. However, the mechanism for the mobilization of CD34+ Thy-1high leukemic cells into the PB is unknown.
我们采用双色流式细胞术分析了CD34⁺急性白血病中Thy-1抗原(CD90)的表达情况。白血病细胞取自57例患者的骨髓(BM)和/或外周血(PB):37例急性髓系白血病(AML)患者,其中9例为骨髓增生异常综合征继发的急性髓系白血病(MDS/AML);20例急性淋巴细胞白血病(ALL)患者,其中3例为淋巴系慢性髓系白血病急变期(CML-BC)。在这些患者中,1例(3.6%)初发AML、2例(22.2%)MDS/AML、3例(17.6%)初发ALL以及2例(66.7%)CML-BC患者的“淋巴细胞”加“原始细胞”窗内超过20%的单核细胞共表达CD34和Thy-1(CD34⁺Thy-1⁺)。Thy-1在初发急性白血病中很少表达,尤其是在AML中。有趣的是,在1例CML-BC患者中,骨髓中的白血病细胞分为两个亚群(CD34⁺Thy-1低和CD34⁺Thy-1高),而外周血中大多数CD34⁺白血病细胞为Thy-1高。然而,CD34⁺Thy-1高白血病细胞动员至外周血的机制尚不清楚。